Journal Content Recommendation
01
Parental willingness of HPV vaccination in Mainland China: A meta-analysis
The pooled awareness rates of HPV and the HPV vaccine among Chinese parents were 45.0% and 41.4%, respectively. The overall parental willingness for vaccinating children against HPV was 61.0%. Both parental awareness and willingness of the HPV vaccine in China were found to remain low when compared to other countries.
https://doi.org/10.1080/21645515.2024.2314381
02
Using big data to analyze the vaccination status of children with congenital heart disease in Yinzhou District, China
Using the China Yinzhou Electronic Health Record Study (CHERRY) database, this study analyzed the vaccination coverage of children with Congenital heart disease (CHD). Compared to their typically developing counterparts, 12-month-old children afflicted with CHD exhibit a slightly diminished vaccination coverage, alongside a discernible inclination toward delayed vaccination. Notably, the determination to undergo vaccinations seems predominantly influenced by the classification of diagnostic medical institutions.
https://doi.org/10.1080/21645515.2024.2319967
03
Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants
This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 (Rotarix™) and RV5 (RotaTeq™) schedules. The study confirms that mixed rotavirus vaccine schedules are non-inferior to standard RV1 and RV5 regimens in terms of immunogenicity and safety. This finding supports the flexibility of rotavirus vaccination strategies, particularly in contexts of vaccine shortage or logistic constraints.
https://doi.org/10.3389/fpubh.2024.1356932
04
A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs
Strategies shown to improve HPV vaccination uptake include campaigns to increase community awareness and knowledge of HPV, health care provider trainings, integrating HPV vaccination within school settings, coordinated efforts via multi-sectoral partnerships, and vaccination reminder and recall systems. Findings may help national authorities understand key considerations for HPV vaccination when designing and implementing programs aiming to increase HPV VCR in adolescents.
https://doi.org/10.1080/21645515.2024.2319426
05
RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes
A phase 3 trial involving pregnant women 18 to 49 years of age to assess the efficacy and safety of a candidate RSV prefusion F protein–based maternal vaccine (RSVPreF3-Mat) was stopped early because of safety concerns. The risks of any and severe medically assessed RSV-associated lower respiratory tract disease among infants were lower with the candidate maternal RSV vaccine than with placebo but that the risk of preterm birth was higher with the candidate vaccine.
https://www.nejm.org/doi/full/10.1056/NEJMoa2305478
Global/National Policy Updates
06
New adjustments to HPV vaccine immunization schedule in Zhejiang and other cities
The Zhejiang Provincial Center for Disease Control and Prevention has announced adjustments to the HPV vaccination schedule. The updated schedule allows for an alternative two-dose regimen for girls aged 9-14: one dose at month 0 and a second dose at month 6, with at least a five-month interval between doses. The three-dose option remains available. Other regions, including Dalian in Liaoning, Harbin in Heilongjiang, and Shijiazhuang in Hebei, have also updated their HPV vaccination schedule recommendation, offering the two-dose regimen for nine-valent HPV vaccine to girls aged 9-14. (Source: People’s Daily Health App)
07
NPC representatives and experts are calling for optimizing China’s immunization strategy
Cui Haixia, NPC representative and Vice Mayor of Hengshui, Hebei Province, Liu Xiaoqing, NPC representative and Director of the Jiangxi Provincial CDC, Chao Shuang, Deputy Director of Pediatrics at Beijing Tsinghua Changgung Hospital, and Feng Zijian, Executive Vice President and Secretary-General of the Chinese Preventive Medicine Association, have urged enhancements to the national immunization plan. They advocate for expanding immunization efforts, focusing on children’s immunization while transitioning to comprehensive, lifelong immunization services for the entire population. (Source: CPPCC Newspaper)
08
Hangzhou launched the “Seven Codes in One” vaccine ID
On March 20, Hangzhou launched the “Seven Codes in One” vaccine ID. This vaccine ID is automatically generated by the system after a citizen receives a vaccination. It includes seven codes to integrate different information from the supply and clinical service chain, including the manufacturer and supply chain tracking code, the vaccine batch number, CDC information, out-patient clinic information, cold chain equipment codes, etc. This information is then sent to the electronic vaccination record in the “Zheli Ban” app, allowing recipients to view their vaccination details the day after they are vaccinated. (Source: Zhejiang Online)
09
Mumps virus vaccines: WHO Position Paper, March 2024
Since the publication of the 2007 WHO position paper on mumps vaccines, there have been reported changes in the epidemiological features of mumps virus infections in several countries after introduction of the vaccines, increased supply and use of measles, mumps and rubella (MMR) vaccines and new evidence on their public health benefits and potential for long-term protection. This document replaces the 2007 WHO position paper on mumps vaccines.
https://www.who.int/publications/i/item/who-wer-9911-115-134
10
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Merck, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
Content Editor: Tianyi Deng
Page Editor: Jiaqi Zu/Ziqi Liu
